India, Oct. 24 -- Genmab A/S (GMAB) and Incyte (INCY) have entered into a clinical trial collaboration to evaluate a novel combination therapy for patients with metastatic colorectal cancer (mCRC) harboring a KRAS G12D mutation, a population with significant unmet medical needs.
Under the agreement, Genmab will lead a Phase 1/2 clinical study assessing its investigational antibody petosemtamab in combination with Incyte's investigational KRAS G12D inhibitor, INCB161734, alongside standard-of-care chemotherapy as a first-line treatment for patients with KRAS G12D-mutated metastatic colorectal cancer.
Petosemtamab is an IgG1-bispecific antibody designed to target both epidermal growth factor receptor (EGFR) and leucine-rich repeat-containin...